• Despite the challenges posed by the COVID pandemic during the past year and a half, music artists have continued producing content and fans have increased their efforts to connect with that content
• Analysts forecast that in the larger entertainment streaming industry, market revenues will grow from the $50 billion recorded early last year to $240 billion by the end of the decade
• Entertainment technology innovator Friendable Inc. has built a platform to capture a share of the streaming market for music artists, helping artists build their own brands and monetize their performances and content in turn
• While the pandemic is widely viewed as the impetus for the astronomical growth of the streaming industry, analysts anticipate the growth trend will continue well beyond the end of the pandemic
• Fan Pass has signed thousands of artists to the platform during the past year, welcoming independent as well as more established artists in an open market opportunity that costs viewers only a few dollars a month

The rapid upscaling of the streaming subscriber market during the ongoing COVID pandemic has now become a pivot point for major companies anticipating that the pandemic will end but the livestream model will continue onward. The merged Warner Bros. Discovery brand’s recent declaration that its existing and planned content is popular enough to drive ongoing revenues through subscriptions despite the consumer trend toward cord-cutting highlights business directives outlined by a multitude of other services in the realm such as Disney+, Paramount Plus and Netflix (https://ibn.fm/0TQIP). Telemedia Online reported Sept. 13 that the video streaming market is expected to grow from the $50 billion revenue mark it posted in early 2020 to “a whopping $240 billion by 2030” with a CAGR in excess of 21 percent as consumers seek entertainment beyond the large original content creators, increasing their use of all major platforms, including social media sites like Instagram and YouTube as working from home also becomes a more common part of their daily lives (https://ibn.fm/Yn96Z). As part of this societal trend groundswell, marketing and mobile entertainment technology innovator Friendable (OTC: FDBL) has pivoted its operating model for building connections between people, working to sell off its once-flagship dating app while turning its attentions toward an emerging platform for driving multi-faceted networking between music artists and their fan consumers. Friendable is nearing the end of a 120-day buildup strategy for the company, launching version 2 of its Fan Pass mobile and web applications with new tech tools to help artists boost their personal brand, increasing public media campaigns, and adding industry talents, partners and BOD support, among other things (https://ibn.fm/6hwin). The company was founded by brothers Robert A. Rositano Jr. and Dean Rositano, who have decades of experience working together on technology-related ventures and a background in the music performance industry. “We had started working on Fan Pass years ago as we started Friendable and launched the company with another mass market opportunity in the dating space. We have pivoted as we developed celebrity relationships and other partners in the artist arena,” Robert, the company’s CEO, told SmallCapVoice in a July interview (https://ibn.fm/LhRa0). “From early days … we’ve formed many relationships in the entertainment community and we’ve done various different things in music over our careers, so it’s timely that the pandemic led us back kind of to our roots.” Fan Pass has expanded its offering with Artist Pro, a suite of services designed to help artists earn a living at a time when live performances are affected by public gathering restrictions. Through Fan Pass, artists can monetize their performances online, create and sell customized merchandise, provide fans with opportunities to not only see performances but gain VIP access to select elements of the artists’ events, and take a direct hand in their own brand development. Artist Pro is currently offered at $8.99. “I get these questions as well: ‘Well, what about as the pandemic lifts and the vaccinations become more widespread?’” Robert Rositano Jr. told SmallCapVoice. “Live events are opening back up. Concerts are coming back in play. That’s what Fan Pass was all about to begin with before the pandemic hit. Fan Pass was all about taking behind-the-scenes or backstage experiences and bringing them to a fanbase that is typically global when we look at a music artist. And a lot of these fans are geographically challenged or maybe not financially able to attend the backstage meet and greet.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

Date: October 11-12, 2021 Online Livestream Dynamic Global Events (“DGE”) is proud to announce its 2nd Risk Evaluation and Mitigation Strategies (“REMS”) virtual summit. This two-day event, scheduled for October 11-12, 2021, will be an excellent avenue for life science professionals to develop decision making skills to adapt to anticipate FDA feedback with ease. This virtual conference is an exceptional resource for gaining new insights into adapting to risk mitigation strategies regarding submissions and modifications. DGE has partnered with BioMed Wire, Pharma Voice, Pharma Marketing Networks, and FDA News Watch, among other enterprises, to offer a wholesome experience to event attendees. They have also customized the program to also appeal to technology vendors, drug safety service providers, pharmacovigilance or drug surveillance specialists, along with data management service providers. This virtual summit will feature top industry experts from critical industry institutions, including Pfizer, Alexion, Merck, CVS, Amneal Pharmaceuticals, GlaxoSmithKline, and Walgreens. Some of the presenters include Kyle Irwin, Operations Lead REMs at Janssen, Jamie Wilkins, Director, Center of Excellence for Risk Management, Worldwide Safety at Pfizer and formerly of the FDA, Nancy Dubois, Associate Director, US Local Safety Officer at Alexion and more. Participants will have an opportunity to interact with these industry leaders, exchange ideas and insights into REMS compliance along with how to communicate with healthcare professionals (“HCPs”), patients, and pharmacies. With the involvement of key advisors within these industries, DGE has developed an agenda that covers all integral aspects of REMS core competencies.  Some of the challenges that will be addressed are how to monitor for risks of inadequate communications, maintaining compliance and inspection readiness, addressing new barriers facing retail pharmacy and specialty pharmacy, and techniques and technologies for effective REMS drug distribution. To learn more about the event, please visit our page https://ibn.fm/FTSBl If interested in attending this virtual event visit https://ibn.fm/rEhSV

• Canadian-based growth-stage company FuelPositive Corp. is building prototypes for a commercially viable and sustainable clean energy ammonia production system that can enable the hydrogen economy by making the transportation and storage of hydrogen easy and economical
• Ammonia has been a carbon-intense industry, but FuelPositive’s Phase 2 Hydrogen-Ammonia Synthesizer is a highly portable and scalable patent-pending solution for rolling out a carbon-free, on site production model to end users
• A report by scientific and technological innovation magazine New Atlas weighs the potential benefits of using ammonia as a means of storing hydrogen for green energy, including ammonia’s ability to “do a better job of storing hydrogen than hydrogen gas itself”
• Renewable energy sources are growing worldwide, and U.S. President Joe Biden has expressed the country’s renewed desire to work with international partners to combat global climate change, and FuelPositive’s technology could resolve concerns about infrastructure

When U.S. President Joe Biden began his term in office with executive actions that defined his support of a clean energy future and sustainable infrastructure, he declared his desire to resume international cooperation in fighting climate change for the first time since the previous administration’s election (https://ibn.fm/iQjgU). This month, the President advanced his policies by declaring a plan to shift half of U.S. energy to solar by 2050. But aside from mapping out a future well beyond when he will be in office, Biden’s plan has drawn skepticism for its expectations of upending current technology and the energy industry to redesign the electric grid from its origins to consumer end use (https://ibn.fm/pBVUc). Such challenges remain a common obstacle in the drive to combat climate change, including questions about the best source for generating renewable energy. Many researchers believe hydrogen is an alluring solution because when hydrogen burns, the only by-product is water. But the traditional process for producing hydrogen from fossil fuels has frustrated clean energy goals. The transportation and storage of hydrogen is also problematic. A new report by science and technology innovation magazine New Atlas describes the benefits of turning to “green ammonia” for the pathway to a new clean fuel that can serve as an alternative to fossil fuels because of its rich hydrogen properties. Ammonia is also known as hydrogen nitride (NH3) because it comprises three hydrogen atoms bonded to one nitrogen atom. “Indeed, in many ways, ammonia does a better job of storing hydrogen than hydrogen gas itself,” the New Atlas report states (https://ibn.fm/yE6vE). “H2 is notorious for leaking away through the metal walls of containers, for embrittling steel it comes into contact with, and for taking a lot of energy to liquefy at cryogenic temperatures. And then there’s density: it may sound weird, but there’s one and a half times more hydrogen in a gallon of ammonia than there is in a gallon of hydrogen, all else being equal.” FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), an innovative company focused on clean energy technologies to address global concerns about climate change, is developing technology that it believes will serve as a cost-effective means of storing and transporting hydrogen via ammonia produced in a carbon-free system as a means of commercializing the process New Atlas’ report describes. The report notes that ammonia carries 70 percent more energy than liquid hydrogen by volume and nearly three times as much energy as compressed hydrogen gas. By weight, ammonia carries more than 20 times as much energy as today’s lithium batteries, the report states. FuelPositive’s patent-pending first-of-its-kind carbon-free ammonia (“NH3”) technology is its Phase 2 Hydrogen-Ammonia Synthesizer, a highly portable and scalable system the company expects to roll out in prototype next year through an agreement with National Compressed Air Canada Ltd. (https://ibn.fm/Ss5rb). FuelPositive anticipates the development of manufacturing, licensing, partnership and acquisition opportunities using its technology. “We think our company will grow a lot in value over the next six to 12 months as our systems are delivered to end users — the people who need FuelPositive’s carbon-free ammonia,” CEO Ian Clifford recently told a group of young investors (https://ibn.fm/VxWtq). “Many people don’t know it, but planes, trains, ships, trucks and other vehicles can be converted to run on pure ammonia – just as easily as they can be converted from gasoline and diesel to run on propane,” Clifford stated in a separate news release (https://ibn.fm/Gebaj). “The transportation sector just didn’t see a benefit to switching to ammonia until now, because the production of traditional ammonia results in massive carbon emissions. But, when you use our carbon-free NH3 made from green electricity rather than traditional ammonia, it means we can move people around and transport goods with no pollution.” Renewable electricity generation is growing at a noteworthy pace in many parts of the world, according to the International Energy Agency (“IEA”), a Paris-based intergovernmental organization. But the IEA also acknowledges that the demand for fossil fuel-based electricity generation is expected to outpace the growth in energy generation from renewable sources for the immediate present as clean energy producers work to accelerate their output (https://ibn.fm/8RRqa). FuelPositive’s technology provides a potential solution for meeting that need for carbon free energy storage and striving toward global 2050 goals. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• 2021 Sequire EdTech Conference announces keynote speaker lineup and agenda featuring founders and leaders of EdTech big names such as Udemy, HolonIQ, Amesite, and more
• Online education and remote work sector have exploded over the past years, attracting growing attention from investors
• Conference aims to bring this growing sector closer to diverse investor audiences, including institutional and retail investors, family offices, venture capitalists and private equity firms, and public and emerging growth companies

SRAX (NASDAQ: SRAX), a financial technology company that developed Sequire, a SaaS platform designed to unlock data and insights for publicly traded companies, has announced an impressive lineup of notable keynote speakers to present at its 2021 Sequire EdTech Conference (https://ibn.fm/6hleu). This one-day investor event featuring more than ten leading virtual work and learning companies is intended for all investors interested in leveraging potential growth opportunities emerging in the world of learning. The world of education has transformed radically since the start of the pandemic, and the question is how the landscape will look in the future and what opportunities lie ahead. A diverse audience, including institutional investors, retail investors, family offices, venture capitalists, public and emerging growth companies, and private equity firms, will have an unparalleled opportunity to meet major figures in the education space to tackle these questions and reveal what’s next for the education industry. Sessions will cover topics such as 5 Major Trends in Education with Patrick Brothers, the Co-Founder & Co-CEO of HolonIQ, a global market intelligence platform for education. Also a member of the World Economic Forum and B20 Education and Employment Task Force of B20, Brothers is committed to revolutionizing how the world learns. Other notable keynote speakers include Dr. Ann Marie Sastry and Mary Juhas, who will host the Higher Education and the Future of Work session. Prior to becoming the President and CEO of Amesite, an award-winning AI software company focused on improving learning, Dr. Sastry co-founded and led Sakti3, a company recognized as one of MIT’s 50 Smartest Companies in 2015. As a scientist with a knack for creating companies that get raved about by their employees (Amesite was the winner of 2020 Best and Brightest Companies to Work For and Sakti3 won the Crain’s Detroit Business Cool Places to Work Prize), Dr. Sastry was also recognized with some of the highest honors in her scientific fields. She will co-host the session with Mary C. Juhas, an associate vice president in the Office of Research at Ohio State University. Juhas is committed to developing research leaders through the recruitment, retention, and advancement of women faculty in the STEM disciplines. The final session, co-hosted by Dr. Sastry and Jonathan Satchell, a training industry veteran with nearly 30 years of experience, will aim to tackle The Coming Decades of Disruptive Innovation in Education. Satchell’s beginnings in the industry date back to 1997 when he acquired EBC, a training video provider he transformed into a bespoke e-learning company. He later became interim MD of Epic, a custom content e-learning company he acquired with Andrew Brode and transformed into LTG, the global, fast-growing, full-service digital learning and talent management company. Other keynote speakers include names such as Julia Pugachevsky, the Education and Personal Development editor on Insider’s Reviews team covering online courses, books, and other career development and self-improvement products, as well as Barbie Brewer, the Chief People Officer at Netflix working passionately to enable remote work and promote inclusiveness. Participants will also have a unique opportunity to participate in the Fireside Chat with Gagan Biyani, an Indian American serial entrepreneur, marketer, and journalist who co-founded Udemy, one of the world’s most renowned online education companies. He will share insights on Lessons from Building an EdTech Unicorn. Virtual work and online learning have been gaining traction over the past few years, offering compelling growth opportunities as the world of remote workplaces and digital classrooms make strides. To view the presentations and keynotes from the 2021 Sequire EdTech Conference visit https://edtech21.mysequire.com/ For more information, visit the company’s websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression
• Administering drug to mice resulted in an approximately 10% increase in neuron size and density
• Cybin is focused on progressing psychedelic therapeutics

As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth. “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reported a “Yale Daily News” article published this week. The article, titled “Yale Researchers Discover Healing Effects of Psychedelic Drug,” stated that, in a paper published in the “Neuron” journal, researchers at the Yale School of Medicine “presented evidence that administering this drug to mice resulted in an approximately 10% increase in neuron size and density in the frontal cortex of the brain. Led by postdoctoral associate Lingxiao Shao and associate professor of psychiatry and neuroscience Alex Kwan, the team found that this ‘structural remodeling’ occurred within 24 hours of the drug administration and persisted for one month, indicating that psilocybin made long-lasting changes in the brain.” In the article, Kwan stated that “psilocybin is fascinating because it has an incredibly short half-life, which means that it gets out of the body quickly and yet has long-lasting behavioral effects. . . . We’ve seen that psilocybin can be effective in treating depression and other neuropsychiatric disorders. In this study, we wanted to investigate this mystery by observing individual connections in the mouse brain.” The paper noted that psilocybin, which is categorized as a psychedelic, is a naturally occurring substance found in a species of fungi often called magic mushrooms. Psilocybin stimulates serotonin 2A receptors in the brain. After psilocybin and other psychedelics were classified as Schedule I drugs during the 1970s, research on the substances slowed significantly. In the past decade, however, research on psychedelics has picked up, with a significant increase in the past few years as evidence grows regarding the potential benefits of the drugs. In the Yale study, Kwan’s team focused on using a mouse model to shed light on the changes the brain undergoes during psychedelic experiences. “Director of Policy and Advocacy at the Multidisciplinary Association for Psychedelic Studies Natalie Ginsberg expressed her excitement about where the field of psychedelic research is headed,” the article concluded. “‘This is totally changing the approach to therapy for PTSD and other mental illnesses,’ Ginsberg said. ‘Psychedelics can also greatly impact people’s connections to nature and to each other. We also hope to see psychedelics decriminalized, making them more safe and accessible to those who can be healed by them.’” Studies like these serve to validate and strengthen the work done by Cybin, which is on a mission to revolutionize mental health care. The company is focused on progressinag psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing
• Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients
• The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls
• Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen was effective in reducing systolic pressure, mean arterial pressure and diastolic pressure as compared with a placebo when monitored for 24 hours

Technology innovator Lexaria Bioscience (NASDAQ: LEXX) is celebrating the initial (partial) results from its human clinical trial pitting its patented flagship platform DehydraTECH (TM), in combination with cannabidiol (“CBD”), against a placebo to measure how blood pressure patients respond to Lexaria’s patented technology. Lexaria’s HYPER-H21-2 human clinical study follows on the heels of initial clinical testing that showed DehydraTECH-CBD produced a reduction in blood pressure in both male and female volunteers and outperformed generic CBD controls in a single-dose regimen studied over the course of three hours (https://ibn.fm/HXctx). The second human clinical study assessed the efficacy of the DehydraTECH-CBD compound in a three-dose schedule over the first half of a 24-hour ambulatory monitoring period. The trial results showed patients who received DehydraTECH-CBD experienced a much greater trending decrease in systolic pressure, mean arterial pressure and diastolic pressure than the placebo during the course of the assessment, according to a Sept. 7 company news release (https://ibn.fm/ZzDjt). Lexaria is pursuing the validation of DehydraTECH-CBD in part because of a market need the company perceives for treating high blood pressure (hypertension), which is a key risk factor for both heart disease and stroke — the leading causes of death experienced by adult populations around the world, including in the United States. High blood pressure, as manifest in systolic pressure, mean arterial pressure and diastolic pressure, is a significant contributing factor to heart attack, stroke and other health threats involving the body’s organs. Lexaria cites other studies that have demonstrated that lowering systolic pressure or diastolic pressure by determined amounts reduced the incidence of coronary artery disease events, both fatal and nonfatal, by double-digit percentages. “Over the initial 24 hours, Lexaria’s 2021 hypertension program is now delivering blood pressure reduction results competitive with — and in some cases even superior to — established oral pharmaceutical hypertension drugs,” CEO Chris Bunka stated in the news release. “DehydraTECH-CBD demonstrated a sustained and augmented effect upon blood pressure attenuation throughout the day, indicating effectiveness of the repeat dosing treatment schedule used in this study.” As documented during the first DehydraTECH-CBD human clinical study, the substance was well tolerated by all of the patients without reports of serious adverse events or side effects, which could help eliminate risks incurred when heart patients stop taking their medications because of discomfort over unwanted effects. Lexaria is now awaiting the complete results on both DehydraTECH-CBD blood pressure human clinical studies, but has already affirmed that it will conduct a third clinical trial later this year related to (pulmonary) hypertension therapies and plans to add a fourth hypertension study that will monitor a larger population of hypertension patients during the course of at least four weeks to establish longer-term performance and tolerability, and to measure inflammatory and oxidative markers also. According to the World Health Organization (“WHO”), an estimated 1.28 billion people have high blood pressure, demonstrating the scale of the potential pharmaceutical market (https://ibn.fm/yFs8J). Transparency Market Research analysts estimate the annual revenues for the hypertension solutions market have reached $28 billion per year and will continue to grow (https://ibn.fm/1xesE). DehydraTECH is designed as a patented technology that improves the bioavailability of pharmaceuticals and therapeutic substances when orally ingested.  Testing has established DehydraTECH’s ability to transform the substances without defeating their effectiveness or creating new molecular entities (“NME”) which are generally subjected to more involved regulatory examination and approval processes than non-NMEs. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space
• The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders
• Tryp has also been keen on collaborating and partnering with key players in the industry, such as Calvert Labs and Gad Consulting services, the University of Michigan, and the University of Florida
• The company also understands the value of proper leadership and, so far in 2021, it has made strategic appointments to its board of directors

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company that has remained focused on developing clinical-stage compounds for diseases with high unmet medical needs. Whereas its focus is on achieving this end through accelerated regulatory pathways, the company also understands the value of innovation, forging the right partnerships, and having exemplary leadership. So far, in 2021, Tryp has made some significant strides from an innovation standpoint, ultimately positioning itself as a first-mover in the psychedelics space.  Its lead drug candidate, TRP-8802, has proven to be promising in treating fibromyalgia (https://ibn.fm/c0oqI). The company believes that psilocybin, a critical component in its drug formulations, can be used more effective in unmet medical needs beyond mental health, and continues to explore that. Tryp has also just announced having completed psychotherapy training and plans to initiate the upcoming phase 2a clinical trial. This trial will utilize synthetic psilocybin in combination with psychotherapy for the treatment of specific overeating disorders. The company announced that the study will be conducted at the University of Florida (“UF”) and will aim at determining the safety and efficacy of psilocybin on hyperphagia (https://ibn.fm/M3hw1). It is a tremendous milestone for Tryp and an indication of its commitment to innovate and find solutions to medical conditions that have not had tangible and reliable treatments. Tryp has not shied away from collaborating and partnering with other players within the industry. In August, Tryp announced its partnership with Calvert Labs and Gad Consulting Services in a move that would facilitate the trial design and execution of the phase 2b clinical trials (https://ibn.fm/cHWZo). Tryp also announced the appointment of Dr. Dan Clauw to its Scientific Advisory Board on the heels of a collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School for the Fibromyalgia phase 2a clinical trial earlier in the year, a critical move for the company. The initiation of clinical trials is an integral step within Tryp’s strategic initiatives in it’s commitment to utilizing the FDA’s 505(b)(2) regulatory pathway, and available third-party preclinical data to shorten the approval timelines and lower the overall cost of development programs (https://ibn.fm/hYjOP). Experienced drug development leadership is also a fundamental aspect of Tryp’s operations. The company’s Chief Executive Officer (“CEO”), Mr. Greg McKee, has continued to successfully Tryp as a pioneer in the psychedelics space. In 2021 alone, the company has brought Mr. McKee onto the management team and made strategic board and advisory appointments, bringing key individuals such as Robin Carhart-Harris and Dennis Langer to help steer the company towards achieving its overall goal (https://ibn.fm/5o0DL). So far, Tryp has managed to have an executive and advisory team that has decades of experience working in leadership positions within critical organizations in the pharmaceutical space, such as Myriad Genetics, Syntex, Dow Chemical, Jubilant, Unigene Laboratories, and Genzyme (https://ibn.fm/VPy1Y).Together, these leaders help push Tryp’s agenda and offer solutions to issues with high unmet medical needs. 2021 has been an excellent year for Tryp, as the company has made incredible strides to further its mission. It is a testament to what can be achieved once a company has the right leadership, forges the right partnerships, and continues to innovate with its products and services. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Through HealthTab, its flagship offering, Avricore turns pharmacies into community diagnostic centers by providing a turnkey point-of-care testing platform
• HealthTab is a multilayered operational ecosystem that provides endless possibilities, from lab-accurate tests to immediate results uploaded automatically on a web-based platform
• It enables patients to review the results on the spot with the pharmacist, allowing pharmacists to take on a more significant role in primary health services
• HealthTab ultimately aims to improve the quality of life for patients living with chronic illnesses

A recent McKinsey article observed that consumers deeply care about wellness now more than ever; this interest is growing by the day (https://ibn.fm/yy5hL). It defined wellness as encompassing better health, better fitness, better nutrition, better appearance, better sleep, and better mindfulness. McKinsey notes that better health, which is perhaps the most traditional category associated with wellness, “extends beyond medicine and supplements to include (consumer) medical devices, telemedicine, and remote healthcare services, as well as personal health trackers.” The article further states that in pursuit of better health, consumers are increasingly taking their health into their own hands, as seen through a rise in the reliance on, among others, devices that help them monitor their own health and symptoms between doctor’s appointments. The better health dimension is particularly important for companies such as Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy services innovator. AVCR is leveraging such consumer health trends along with technological advancements to provide direct access to lab-accurate tests that measure and monitor conditions such as heart disease and diabetes. Through its flagship offering and wholly owned subsidiary, HealthTab(TM), the company turns pharmacies into community diagnostic centers by providing a turnkey point-of-care testing platform. HealthTab achieves this through a multilayered operational ecosystem that offers endless possibilities within a single platform, which first prompts the patient to create an account before using it. HealthTab utilizes the laboratory-accurate analyzers – Abbott’s Afinion 2(TM) and ID Now, as well as I-STAT – to provide valuable point-of-care screening at community pharmacies for various diseases and conditions, including diabetes, heart disease, kidney function, respiratory syncytial virus (“RSV”), influenza A and B, and Strep. Once a patient visits a pharmacy that offers HealthTab, they provide a tiny sample with a simple finger prick or swap. Currently, the platform tests and tracks a total of 23 biomarkers (https://ibn.fm/Go2Bu). The platform, which brings these analyzers into a single, secure, cloud-based network, automatically uploads each patient’s results to their respective health dashboard, meaning the patients can access their results on the spot, as well as review them with the pharmacist. With the insights contained in the results, patients can then take steps to a healthier future with the help of the pharmacist and doctor. In so doing, the HealthTab platform enables pharmacists to take on a greater role in primary health services and recent comments by a Mississauga, Ontario-based pharmacist Mohamed Adel Elsabakhawi, attest to this. On June 3, Avricore announced the rollout of a pilot program in which patients would have access to HealthTab and its testing and monitoring capabilities at select Shoppers Drug Mart locations. It then conducted an initial trial of the platform in an Ontario, Canada Shopper Drug Mart (https://ibn.fm/OBVRX). It was during this week-and-a-half trial period that Mohamed, who is also the Ontario store’s associate owner and first pharmacist to operate the platform, interacted with it. “I’m so excited to have HealthTab in my store because I believe this is going to demonstrate a new and better way to do pharmacy practice,” Mohamed had said (https://ibn.fm/mP8Yc). “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively.” In addition to enabling pharmacists to take on a more significant role in primary health services, HealthTab is capitalizing on the burgeoning point-of-care testing market expected to grow from an estimated $43.49 billion in 2021 to $81.37 billion in 2028, representing a 9.4% CAGR during the forecast period (https://ibn.fm/QTrSh). Nonetheless, Avricore ultimately aims to improve the quality of life for patients living with chronic illnesses. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• The $6 million investment round was led by Crawford Hoying, a real estate holding company with more than $1.3 billion of mixed-use, multifamily, office, and retail properties
• The company is taking advantage of the new wave of investment opportunities in the emerging industry Airbnb has created
• Equity in reAlpha properties can be purchased for as little as $2,500 and handled much like buying stock in a company. Investors are matched with like-minded backers to cover the down payment on properties

reAlpha, often referred to as the Robinhood of Airbnb investments, recently announced that it has closed on a $6 million investment round. The lead investor of the round was real estate holding company Crawford Hoying, which has developed more than $1.3 billion of mixed-use, multifamily, office and retail properties. The new funding that reAlpha has received is set to accelerate the company’s growth, including its innovative short-term rental investment platform, data science function, and engineering capabilities. Proceeds will also be used to expand reAlpha’s geographical presence, operations, and member network (https://ibn.fm/xWiVQ). “reAlpha enables superior alpha yield by investing in short-term rental properties. We have simplified the entire process of investing and managing these properties using advanced technologies. This allows ‘Mainstreet’ investors to access the real estate investment market like never before,” said reAlpha CEO Giri Devanur. The founder of Crawford Hoying, Brent Crawford, called reAlpha’s proprietary technology a paradigm shift for the short-term rental investment market. “The proprietary technology developed to identify, acquire, and market properties with lower risk is a big leap. We strongly believe in the team’s conviction and vision to scale this into a leader in this space,” he said. Based on statements by reAlpha, a new wave of investment opportunities in the real estate industry is emerging, spurred by the heightened desire for short-term rentals and private accommodations which have only been accelerated post-pandemic. reAlpha’s model allows consumers to benefit from the superior returns of short-term rental income and the increase in property value through renovations and market appreciation conditions. Investors can invest in these short-term rental and vacation homes through the company’s platform and partner broker-dealer site, democratizing the market’s access. For an investment of as little as $2,500, first through the reAlpha app and then connected through to a broker dealer site, investors can purchase equity in a specific reAlpha property, much like buying stock in a company. The company matches members with other like-minded backers to form a syndicate, together covering a down payment on the property that has been selected. Most investment properties require a 25 percent down payment, but with reAlpha, that reduces to 10 percent because of the relationships the company has developed and nurtured with lenders. The company handles all property management functions and believes that short-term rentals are no longer just for transactional purposes. reAlpha reimagines the entire guest experience end-to-end, making sure that reAlphaHouse is the ultimate on-demand rental property. Targeting specific markets across the globe, reAlpha’s preference is to purchase 100 to 500 of these short-term rental properties in each market. When acquiring the properties, reAlpha uses its artificial intelligence technology “reAlphaBRAIN” to select specific unicorn properties — zeroing in on the best available opportunities in the market. The software quickly evaluates thousands of property listings based on 25+ factors, assigning each a reAlphaScore. The score projects how Airbnb-viable the property is, including the projected value in the property market. Through its innovative platform and unique approach, reAlpha is set to secure a leading position for itself and its members in the global short-term rental market. According to Airbnb’s recent IPO filing, the global short-term rental market is valued at $1.2 trillion. The global vacation rental segment is anticipated to expand at a CAGR of 3.4 percent from 2020 to 2027, and reach $113.9 billion in 2027, with millennials being the primary driving force of this growth (https://ibn.fm/jgviA). Research has indicated that 71 percent of those traveling, especially with kids, prefer to cook their meals while traveling, which is a major reason for the vacation rental market boost. For more information, visit the company’s website at www.reAlpha.com. NOTE TO INVESTORS: The latest news and updates relating to reAlpha are available in the company’s newsroom at https://ibn.fm/reAlpha

Date: September 22-24, 2021 Online Livestream Pharma professionals, healthcare providers, influencers, and healthcare-related industries are invited to attend DGE’s 7th Advancing Women’s Leadership Skills & Opportunities in Pharma & Healthcare being held on September 22-24, 2021, as a live online event. The event is organized by Dynamic Global Events (“DGE”), a Life Science leader in hosting B2B events. This global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.  Women executives in the pharma and healthcare sector face numerous hurdles to reach the echelon of success. The event will feature such inspiring success stories that educate the next generation of leaders. The conference aims to educate, inform, and empower women in leadership roles to bridge the gender disparity gaps in the industry. The live streaming event platform will serve as a vast learning ground for aspiring women medical and healthcare professionals about managing their roles as a leader, dealing with work obstacles and getting the most out of their team. The event will feature eminent speakers and dignitaries who have steadily paved their way up using their leadership skills in the medical industry. These power-packed sessions will assist new medical professionals in enhancing their skills for greater boost their career growth. The opening day of the conference will feature a keynote session by Jeffery Tobias Halter, President of YWOMEN, Gender Strategist, about his book, WHY WOMEN – The Leadership Imperative to Advancing Women and Engaging Men. In this session, he will discuss the tools and steps that should be taken for the long-term advancement of women. While the program pivots around advancing women, it will also explore other factors of diversity including race, age and gender non-binary. The session will discuss ways to create an Integrated Women’s Leadership Strategy designed for growth and enhanced company reputation. They will further examine steps to engage men as allies and advocates for women leadership. Other industry sharing topics of the conference include

• Learning from the best women leaders
• Getting visibility and great work opportunities in the virtual workplace
• Resurrecting and realigning your workplace activities post the pandemic
• Attaining your leadership role and getting a seat on the board of director

To know more about the event, please visit https://ibn.fm/BSuZC